Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCI-1038
- Development stage
- Unknown
- Lead developer
- BrainCells
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BCI-1038 is a pro-drug candidate developed by BrainCells Inc. It is currently undergoing evaluation in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetic profile in healthy male subjects. Administered as a single oral dose, BCI-1038 is one of several new pro-drugs being investigated, and it is being compared to BCI-838 and its active metabolite BCI-632. This suggests that BCI-1038 is designed to deliver BCI-632 as its active therapeutic agent.
- Other names
- BCI-632BCI632BCI 632MGS0039MGS-0039MGS 0039
02
Targets
GRM3 (mGluR3)GRM2 (mGluR2)
Beyond the preview
Go deeper on BCI-1038.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCI-1038.